Merck Korea CEO Defends Controversial FTA With U.S., Cites Drug Access
This article was originally published in PharmAsia News
Executive Summary
Merck Korea CEO Juergen Koenig defends the nation’s Free Trade Agreement agreed with the U.S. that has become highly controversial in South Korea’s business community.